104 related articles for article (PubMed ID: 22465063)
21. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
22. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network.
Rosen H; Goetzl EJ
Nat Rev Immunol; 2005 Jul; 5(7):560-70. PubMed ID: 15999095
[TBL] [Abstract][Full Text] [Related]
23. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA; Weinstock-Guttman B
Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
[TBL] [Abstract][Full Text] [Related]
24. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
25. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
Van Doorn R; Van Horssen J; Verzijl D; Witte M; Ronken E; Van Het Hof B; Lakeman K; Dijkstra CD; Van Der Valk P; Reijerkerk A; Alewijnse AE; Peters SL; De Vries HE
Glia; 2010 Sep; 58(12):1465-76. PubMed ID: 20648639
[TBL] [Abstract][Full Text] [Related]
26. Enzymatic kinetics regarding reversible metabolism of CS-0777, a sphingosine 1-phosphate receptor modulator, via phosphorylation and dephosphorylation in humans.
Inaba SI; Yamaguchi-Goto M; Tanaka-Takanaka K; Yonesu K; Sakurai H; Kubota K; Izumi T
Xenobiotica; 2018 Mar; 48(3):258-268. PubMed ID: 28287856
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis.
Inaba SI; Goto M; Tanaka-Takanaka K; Tanaka H; Tomisato W; Yuita H; Doi-Komuro H; Inoue R; Oshima K; Kagari T; Shimozato T; Izumi T
Biopharm Drug Dispos; 2016 Dec; 37(9):561-573. PubMed ID: 27764535
[TBL] [Abstract][Full Text] [Related]
28. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
29. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
[TBL] [Abstract][Full Text] [Related]
30. Defective T cell chemotaxis to sphingosine 1-phosphate and chemokine CCL21 in idiopathic T lymphocytopenia.
Goetzl EJ; Schwartz JB; Huang MC
J Clin Immunol; 2011 Oct; 31(5):744-51. PubMed ID: 21671128
[TBL] [Abstract][Full Text] [Related]
31. FTY720 modulates human oligodendrocyte progenitor process extension and survival.
Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP
Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine-1-phosphate and oligodendrocytes: from cell development to the treatment of multiple sclerosis.
Coelho RP; Saini HS; Sato-Bigbee C
Prostaglandins Other Lipid Mediat; 2010 Apr; 91(3-4):139-44. PubMed ID: 19808013
[TBL] [Abstract][Full Text] [Related]
33. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors.
Bassi R; Anelli V; Giussani P; Tettamanti G; Viani P; Riboni L
Glia; 2006 Apr; 53(6):621-30. PubMed ID: 16470810
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine-1-phosphate signaling in the cardiovascular system.
Peters SL; Alewijnse AE
Curr Opin Pharmacol; 2007 Apr; 7(2):186-92. PubMed ID: 17280869
[TBL] [Abstract][Full Text] [Related]
35. First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
Bergougnan L; Armani S; Golor G; Tardat A; Vitse O; Hurbin F; Scemama M; Poitiers F; Radzik D; Gaudin C; Hovsepian L; Muslin AJ; Kirkesseli S; Deutsch P; Parkar AA
Br J Clin Pharmacol; 2021 Feb; 87(2):598-611. PubMed ID: 32520410
[TBL] [Abstract][Full Text] [Related]
36. Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate.
Dueñas AI; Aceves M; Fernández-Pisonero I; Gómez C; Orduña A; Crespo MS; García-Rodríguez C
Cardiovasc Res; 2008 Aug; 79(3):537-44. PubMed ID: 18411230
[TBL] [Abstract][Full Text] [Related]
37. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses.
Wei SH; Rosen H; Matheu MP; Sanna MG; Wang SK; Jo E; Wong CH; Parker I; Cahalan MD
Nat Immunol; 2005 Dec; 6(12):1228-35. PubMed ID: 16273098
[TBL] [Abstract][Full Text] [Related]
38. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D
Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254
[TBL] [Abstract][Full Text] [Related]
39. The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases.
Japtok L; Kleuser B
Curr Opin Investig Drugs; 2009 Nov; 10(11):1183-94. PubMed ID: 19876786
[TBL] [Abstract][Full Text] [Related]
40. Roles for N-glycosylation in the dynamics of Edg-1/S1P1 in sphingosine 1-phosphate-stimulated cells.
Kohno T; Igarashi Y
Glycoconj J; 2004; 21(8-9):497-501. PubMed ID: 15750791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
